
Craig C Hofmeister

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9487069/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Initial genome sequencing and analysis of multiple myeloma. Nature, 2011, 471, 467-472.	27.8	1,288
2	Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2012, 366, 1770-1781.	27.0	1,024
3	The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody. Blood, 2010, 116, 2286-2294.	1.4	716
4	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood, 2014, 123, 1826-1832.	1.4	327
5	Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunology, Immunotherapy, 2013, 62, 1841-1849.	4.2	258
6	A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood, 2012, 120, 4324-4333.	1.4	217
7	Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche. Bone Marrow Transplantation, 2007, 39, 11-23.	2.4	190
8	IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood, 2011, 118, 6387-6391.	1.4	184
9	Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 230-269.	4.9	166
10	A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2015, 21, 4055-4061.	7.0	154
11	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2020, 38, 1928-1937.	1.6	148
12	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 11-20.	4.9	142
13	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematology,the, 2017, 4, e431-e442.	4.6	132
14	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Journal of Experimental Medicine, 2013, 210, 951-968.	8.5	121
15	Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nature Communications, 2019, 10, 1911.	12.8	109
16	Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy. JCI Insight, 2019, 4, .	5.0	107
17	Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. Blood, 2018, 131, 855-863.	1.4	105
18	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer Journal, 2019, 9, 94.	6.2	104

#	Article	IF	CITATIONS
19	Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells. Clinical Cancer Research, 2014, 20, 3989-4000.	7.0	103
20	Daratumumab in multiple myeloma. Cancer, 2019, 125, 2364-2382.	4.1	100
21	Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2009, 15, 1422-1430.	2.0	89
22	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood, 2011, 118, 535-543.	1.4	82
23	MicroRNAs activate natural killer cells through Toll-like receptor signaling. Blood, 2013, 121, 4663-4671.	1.4	82
24	Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein. Journal of Clinical Oncology, 2011, 29, 3427-3434.	1.6	77
25	A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma. Clinical Cancer Research, 2014, 20, 5946-5955.	7.0	72
26	Symphony: view-driven software architecture reconstruction. , 0, , .		68
27	Addition of Infliximab to Standard Acute Graft-versus-Host Disease Prophylaxis following Allogeneic Peripheral Blood Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 783-789.	2.0	68
28	Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. Journal of Proteomics, 2016, 136, 89-98.	2.4	68
29	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood, 2016, 127, 2693-2700.	1.4	66
30	Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. Journal of Geriatric Oncology, 2019, 10, 479-485.	1.0	64
31	Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. Leukemia and Lymphoma, 2013, 54, 1658-1664.	1.3	63
32	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 389-400.	4.9	62
33	Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia, 2021, 35, 189-200.	7.2	56
34	Retrospective utility of bronchoscopy after hematopoietic stem cell transplant. Bone Marrow Transplantation, 2006, 38, 693-698.	2.4	55
35	Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia, 2014, 28, 1922-1926.	7.2	55
36	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia, 2020, 34, 1840-1852.	7.2	55

#	Article	IF	CITATIONS
37	Multiple Myeloma, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1398-1435.	4.9	55
38	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia, 2020, 34, 2430-2440.	7.2	54
39	Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplantation, 2016, 51, 1241-1244.	2.4	53
40	Ninety-minute daratumumab infusion is safe in multiple myeloma. Leukemia, 2018, 32, 2495-2518.	7.2	53
41	Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer, 2001, 92, 2334-2340.	4.1	51
42	The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo. PLoS ONE, 2010, 5, e10941.	2.5	49
43	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood, 2021, 137, 3604-3615.	1.4	44
44	A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leukemia and Lymphoma, 2017, 58, 2310-2318.	1.3	43
45	Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. British Journal of Cancer, 2014, 111, 272-280.	6.4	42
46	Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. OncoImmunology, 2018, 7, e1486948.	4.6	41
47	Allogeneic Stem Cell Transplantation for Patients with Relapsed Chemorefractory Aggressive Non-Hodgkin Lymphomas. Biology of Blood and Marrow Transplantation, 2009, 15, 547-553.	2.0	39
48	HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget, 2015, 6, 31134-31150.	1.8	38
49	Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma. Bone Marrow Transplantation, 2015, 50, 1379-1381.	2.4	36
50	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer, 2019, 125, 416-423.	4.1	36
51	Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 110-112.	3.0	35
52	Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. Molecular Cancer Therapeutics, 2016, 15, 830-841.	4.1	35
53	Tocilizumab for steroid refractory acute graft-versus-host disease. Leukemia and Lymphoma, 2016, 57, 81-85.	1.3	35
54	Graft-versus-host disease of the skin: life and death on the epidermal edge. Biology of Blood and Marrow Transplantation, 2004, 10, 366-372.	2.0	34

#	Article	IF	CITATIONS
55	Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematology,the, 2017, 4, e24-e34.	4.6	33
56	Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma. Molecular Therapy - Oncolytics, 2017, 5, 87-96.	4.4	33
57	MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. JCI Insight, 2019, 4, .	5.0	33
58	Characterization of Multiple Myeloma Vesicles by Label-Free Relative Quantitation. Proteomics, 2013, 13, n/a-n/a.	2.2	32
59	Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104. Blood, 2010, 116, 37-37.	1.4	31
60	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. Journal of Clinical Oncology, 2022, 40, 3057-3064.	1.6	31
61	A phase I trial of flavopiridol in relapsed multiple myeloma. Cancer Chemotherapy and Pharmacology, 2014, 73, 249-257.	2.3	30
62	Twiceâ€weekly ixazomib in combination with lenalidomideâ€dexamethasone in patients with newly diagnosed multiple myeloma. British Journal of Haematology, 2018, 182, 231-244.	2.5	30
63	Polymorphism in <i>ANRIL</i> is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. Molecular Carcinogenesis, 2017, 56, 1722-1732.	2.7	28
64	Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). Blood, 2011, 118, 302-302.	1.4	28
65	Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma. Therapeutic Drug Monitoring, 2008, 30, 620-627.	2.0	27
66	The potential of miRNAs as biomarkers for multiple myeloma. Expert Review of Molecular Diagnostics, 2014, 14, 947-959.	3.1	23
67	Granulocyte Colony-Stimulating Factor–Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 658-668.	2.0	23
68	A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (<scp>MLN</scp> 8237) and Bortezomib in Relapsed Multiple Myeloma. British Journal of Haematology, 2016, 174, 323-325.	2.5	22
69	The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma. Bone Marrow Transplantation, 2014, 49, 1323-1329.	2.4	21
70	Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 262-268.	2.8	21
71	Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. British Journal of Haematology, 2015, 171, 74-83.	2.5	20
72	How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma. Journal of Clinical Oncology, 2016, 34, 4421-4430.	1.6	20

#	Article	IF	CITATIONS
73	Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein–Barr virus DNA PCR. Bone Marrow Transplantation, 2007, 39, 249-251.	2.4	19
74	Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leukemia and Lymphoma, 2015, 56, 1058-1065.	1.3	19
75	Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients. Bone Marrow Transplantation, 2018, 53, 1418-1427.	2.4	19
76	Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma. Blood, 2008, 112, 2770-2770.	1.4	19
77	Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data. Blood, 2013, 122, 535-535.	1.4	18
78	TTP disease course is independent of myeloma treatment and response. American Journal of Hematology, 2010, 85, 304-306.	4.1	17
79	FLT3L and Plerixafor Combination Increases Hematopoietic Stem Cell Mobilization and Leads to Improved Transplantation Outcome. Biology of Blood and Marrow Transplantation, 2014, 20, 309-313.	2.0	17
80	A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2021, 87, 599-611.	2.3	16
81	Clinical Utility of Autopsy after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 26-30.	2.0	15
82	Effects of induction with novel agentsversusconventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. Leukemia and Lymphoma, 2010, 51, 243-251.	1.3	15
83	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. Clinical Cancer Research, 2021, 27, 3178-3189.	7.0	15
84	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. Blood Cancer Discovery, 2021, 2, 600-615.	5.0	15
85	Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM) Journal of Clinical Oncology, 2015, 33, 8523-8523.	1.6	15
86	Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfanâ€based reduced toxicity conditioning. Hematological Oncology, 2011, 29, 202-210.	1.7	14
87	Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. Supportive Care in Cancer, 2014, 22, 2911-2916.	2.2	14
88	Early phase clinical studies of <scp>AR</scp> â€42, a histone deacetylase inhibitor, for neurofibromatosis type 2â€associated vestibular schwannomas and meningiomas. Laryngoscope Investigative Otolaryngology, 2021, 6, 1008-1019.	1.5	14
89	Induced Resistance to Bortezomib in Preclinical Model of Waldenstrom Macroglobulinemia Is Associated with Bcl-2 Upregulation Blood, 2009, 114, 4919-4919.	1.4	14
90	Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM) Blood, 2009, 114, 431-431.	1.4	13

#	Article	IF	CITATIONS
91	A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,. Blood, 2011, 118, 3701-3701.	1.4	13
92	Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. Leukemia Research, 2008, 32, 1295-1298.	0.8	12
93	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). Blood, 2013, 122, 1969-1969.	1.4	12
94	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). Blood, 2015, 126, 3036-3036.	1.4	12
95	Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial. Blood, 2016, 128, 1346-1346.	1.4	12
96	Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT). Biology of Blood and Marrow Transplantation, 2016, 22, 71-79.	2.0	11
97	Pharmacokineticâ€Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving Highâ€Dose Melphalan for Autologous Stem Cell Transplant. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 748-758.	2.5	11
98	Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. European Journal of Haematology, 2019, 102, 494-503.	2.2	11
99	Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. Blood, 2018, 132, 3282-3282.	1.4	11
100	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. Blood, 2012, 120, 450-450.	1.4	11
101	First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2015, 126, 1838-1838.	1.4	11
102	A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. American Journal of Hematology, 2022, 97, .	4.1	11
103	Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents. Hematological Oncology, 2012, 30, 156-162.	1.7	10
104	A Single Nucleotide Polymorphism in <i>SLC7A5</i> Was Associated With Clinical Response in Multiple Myeloma Patients. Anticancer Research, 2019, 39, 67-72.	1.1	10
105	Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM). Blood, 2018, 132, 1994-1994.	1.4	10
106	Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial. Blood, 2019, 134, 602-602.	1.4	10
107	A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma. Blood, 2016, 128, 4509-4509.	1.4	10
108	Unique Pattern of Renal κ Light Chain Amyloid Deposition With Histiocytic Transdifferentiation of Tubular Epithelial Cells. American Journal of Surgical Pathology, 2012, 36, 1253-1257.	3.7	9

#	Article	IF	CITATIONS
109	BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, 1107-1115.	2.0	9
110	Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results. Blood, 2011, 118, 634-634.	1.4	9
111	MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. Blood, 2012, 120, 727-727.	1.4	9
112	Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM). Blood, 2015, 126, 728-728.	1.4	9
113	Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma. Blood, 2010, 116, 3564-3564.	1.4	9
114	Mucosal protection by cytokines. Psychophysiology, 2005, 4, 446-53.	1.1	9
115	The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2008, 14, 351-352.	2.0	8
116	Chemotherapeutic Agents Increase the Risk for Pulmonary Function Test Abnormalities in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 325-329.	0.4	8
117	Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer. Medical Oncology, 2013, 30, 358.	2.5	8
118	Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization. Leukemia Research, 2019, 85, 106215.	0.8	8
119	Population pharmacokinetics of lenalidomide in patients with Bâ€cell malignancies. British Journal of Clinical Pharmacology, 2019, 85, 924-934.	2.4	8
120	Oncolytic herpes simplex virus infects myeloma cells inÂvitro and inÂvivo. Molecular Therapy - Oncolytics, 2021, 20, 519-531.	4.4	8
121	Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events Blood, 2009, 114, 3416-3416.	1.4	8
122	Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma. Blood, 2013, 122, 1853-1853.	1.4	8
123	Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM). Blood, 2014, 124, 4773-4773.	1.4	8
124	TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients. Blood, 2015, 126, 3052-3052.	1.4	8
125	Evaluation of pulmonary infiltrates in patients after stem cell transplantation. Hematology, 2005, 10, 469-481.	1.5	7
126	A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. Leukemia and Lymphoma, 2015, 56, 1043-1049.	1.3	7

#	Article	IF	CITATIONS
127	XRCC1â€mediated DNA repair is associated with progressionâ€free survival of multiple myeloma patients after autologous stem cell transplant. Molecular Carcinogenesis, 2019, 58, 2327-2339.	2.7	7
128	Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. Blood Cancer Journal, 2020, 10, 125.	6.2	7
129	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. American Journal of Hematology, 2021, 96, E68-E71.	4.1	7
130	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial Blood, 2009, 114, 132-132.	1.4	7
131	The Majority of Myeloma Patients Are Vitamin D Deficient, Unrelated to Survival or Cytogenetics. Blood, 2015, 126, 5336-5336.	1.4	7
132	Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma Blood, 2009, 114, 2884-2884.	1.4	7
133	BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas. Bone Marrow Transplantation, 2019, 54, 1553-1561.	2.4	6
134	Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial. Blood, 2018, 132, 123-123.	1.4	6
135	Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH) Tj ETQq1 1 2010, 116, 3966-3966.	0.784314 1.4	rgBT /Overloci 6
136	Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT). Blood, 2012, 120, 1942-1942.	1.4	6
137	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications–2. Mayo Clinic Proceedings, 2010, 85, 197-199.	3.0	5
138	Characterizing Pain Experiences: African American Patients With Multiple Myeloma Taking Around-the-Clock Opioids. Clinical Journal of Oncology Nursing, 2020, 24, 538-546.	0.6	5
139	Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant. British Journal of Clinical Pharmacology, 2020, 86, 2165-2173.	2.4	5
140	Long Term Therapy with Lenalidomide in a patient with POEMS Syndrome. European Journal of Case Reports in Internal Medicine, 2014, 1, .	0.4	5
141	Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. Transplantation and Cellular Therapy, 2022, 28, 75.e1-75.e7.	1.2	5
142	A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results. Blood, 2012, 120, 4058-4058.	1.4	5
143	Phase I Adjuvant Radiation With Docetaxel in High-Risk Head and Neck Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 396-400.	1.3	4
144	Standard Pentostatin Dose Reductions in Renal Insufficiency Are Not Adequate: Selected Patients with Steroid-Refractory Acute Graft-Versus-Host Disease. Clinical Pharmacokinetics, 2013, 52, 705-712.	3.5	4

#	Article	IF	CITATIONS
145	G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. Leukemia and Lymphoma, 2017, 58, 2947-2951.	1.3	4
146	Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up. Biology of Blood and Marrow Transplantation, 2020, 26, 44-49.	2.0	4
147	Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. Anticancer Research, 2020, 40, 5707-5713.	1.1	4
148	Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma Blood, 2012, 120, 2955-2955.	1.4	4
149	Reolysin Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients. Blood, 2015, 126, 1835-1835.	1.4	4
150	Exploring the Possibility of Using Herpes Simplex Virus in Oncolytic Virotherapy of Multiple Myeloma. Blood, 2016, 128, 4467-4467.	1.4	4
151	C-CSF Starting Day +1 after Autologous Transplant Is Safer Than Day +5 or Day +7 in Patients with Multiple Myeloma. Blood, 2016, 128, 5790-5790.	1.4	4
152	Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. Blood, 2017, 130, 902-902.	1.4	4
153	A Single Nucleotide Polymorphism (SNP) in the <i>SLC22A3</i> Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy. Anticancer Research, 2022, 42, 385-395.	1.1	4
154	Most multiple myeloma patients have low testosterone. Leukemia and Lymphoma, 2019, 60, 836-838.	1.3	3
155	Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 5647-5647.	1.4	3
156	A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma. Blood, 2013, 122, 3181-3181.	1.4	3
157	2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial. Blood, 2014, 124, 3960-3960.	1.4	3
158	Anti-Depressant Use in Patients with Multiple Myeloma Less Common Than Expected. Blood, 2016, 128, 2420-2420.	1.4	3
159	Daratumumab Impairs Myeloma Cell Adhesion Mediated Drug Resistance through CD38 Internalization. Blood, 2016, 128, 4479-4479.	1.4	3
160	MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM) Journal of Clinical Oncology, 2013, 31, 8584-8584.	1.6	3
161	Importin-β and exportin-5 are strong biomarkers of productive reoviral infection of cancer cells. Annals of Diagnostic Pathology, 2018, 32, 28-34.	1.3	2
162	Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?. Bone Marrow Transplantation, 2019, 54, 913-916.	2.4	2

#	Article	IF	CITATIONS
163	Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses. Blood, 2018, 132, 2655-2655.	1.4	2
164	Safety and Efficacy of Evomelaâ,,¢ in Myeloma Autotransplants. Blood, 2018, 132, 3446-3446.	1.4	2
165	Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. Blood, 2018, 132, 3294-3294.	1.4	2
166	The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics Blood, 2010, 116, 3803-3803.	1.4	2
167	Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance. Blood, 2012, 120, 2004-2004.	1.4	2
168	T-Cell p16INK4A Expression Increases Post-Transplant in Patients with Multiple Myeloma. Blood, 2014, 124, 2023-2023.	1.4	2
169	Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients. Blood, 2015, 126, 3200-3200.	1.4	2
170	Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). Blood, 2014, 124, 1166-1166.	1.4	2
171	Wavelet analysis of SAECG to identify patients with conduction defects at risk for sudden cardiac death. Biomedical Sciences Instrumentation, 1997, 33, 497-502.	0.2	2
172	Reply to N. Chen et al. Journal of Clinical Oncology, 2012, 30, 341-342.	1.6	1
173	Improving Vaccination of Patients Pre and Post Bone Marrow Transplant. Biology of Blood and Marrow Transplantation, 2012, 18, S380.	2.0	1
174	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. Blood, 2018, 132, 3241-3241.	1.4	1
175	Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy. Blood, 2018, 132, 1884-1884.	1.4	1
176	Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma. Blood, 2019, 134, 1816-1816.	1.4	1
177	Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials. Blood, 2019, 134, 4525-4525.	1.4	1
178	IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect Blood, 2009, 114, 3870-3870.	1.4	1
179	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial. Blood, 2010, 116, 1937-1937.	1.4	1
180	Phase I Study of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma. Blood, 2012, 120, 1859-1859.	1.4	1

#	Article	IF	CITATIONS
181	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure. Blood, 2012, 120, 4070-4070.	1.4	1
182	Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD). Blood, 2012, 120, 4192-4192.	1.4	1
183	The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma. Blood, 2012, 120, 4286-4286.	1.4	1
184	Low Testosterone Levels Are Associated with Shorter Progression Free Survival in Multiple Myeloma. Blood, 2012, 120, 4978-4978.	1.4	1
185	A Phase 1 Trial Of Reolysin Alone In Patients With Refractory Or Relapsed Multiple Myeloma. Blood, 2013, 122, 3208-3208.	1.4	1
186	Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 807-816.	1.6	1
187	Autopsies Post Hematopoietic Stem Cell Transplant: A Reassessment of Their Role in Patient Management Blood, 2005, 106, 1332-1332.	1.4	1
188	Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results Blood, 2009, 114, 2880-2880.	1.4	1
189	IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data. Blood, 2010, 116, 1966-1966.	1.4	1
190	Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia. Blood, 2010, 116, 1933-1933.	1.4	1
191	Development of a Predictive Pharmacokinetic and Pharmacodynamic Model to Personalize Melphalan Dosing in Autologous Transplant for Patients with Multiple Myeloma. Blood, 2014, 124, 1086-1086.	1.4	1
192	HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide. Blood, 2014, 124, 3377-3377.	1.4	1
193	The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study. Blood, 2018, 132, 5911-5911.	1.4	1
194	Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies. Blood, 2021, 138, 3134-3134.	1.4	1
195	Impact of concurrent gabapentin or pregabalin with highâ€dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Pharmacotherapy, 2022, 42, 233-240.	2.6	1
196	Title is missing!. Cardiovascular Engineering (Dordrecht, Netherlands), 2002, 2, 33-35.	1.0	0
197	Impact of Atorvastatin On Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). Biology of Blood and Marrow Transplantation, 2013, 19, S202.	2.0	0
198	Autologous Hematopoietic Stem Cell Transplant (aHSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL amyloidosis). Biology of Blood and Marrow Transplantation, 2013, 19, S186.	2.0	0

#	Article	IF	CITATIONS
199	Improved Survival of Patients (Pts) with Acute Graft-Versus-Host Disease (aGVHD) During Recent Years: Impact of Donor and Recipient Characteristics. Biology of Blood and Marrow Transplantation, 2013, 19, S320-S321.	2.0	Ο
200	Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity (RIC) Allogeneic Hematopoeitic Stem Cell Transplant (HSCT). Biology of Blood and Marrow Transplantation, 2013, 19, S304-S305.	2.0	0
201	High-Risk Myeloma: When To Transplant—Or Not. Seminars in Oncology, 2014, 41, e1-e9.	2.2	Ο
202	Utility of CMV PCR in the Evaluation of Allograft Recipients Presenting with Diarrhea. Biology of Blood and Marrow Transplantation, 2014, 20, S250-S251.	2.0	0
203	A Potential Role for Auto-Graft Immune Cell Subsets to Influence Post-Transplant Outcomes in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, S131.	2.0	0
204	Phase 1/2 dose-escalation study of marizomib (MRZ, NPI-0052) plus low dose dexamethasone (DEX) in patients with relapsed and refractory multiple myeloma; study NPI-0052-101 (NCT00461045). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e271-e272.	0.4	0
205	Antithymocyte Globulin (ATG) 4.5 Vs. 6.0 Mg/Kg in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT). Biology of Blood and Marrow Transplantation, 2016, 22, S316-S317.	2.0	0
206	Registering a CD38 antibody upfront for multiple myeloma. Lancet, The, 2019, 394, 3-4.	13.7	0
207	The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Patients with Multiple Myeloma Blood, 2007, 110, 5129-5129.	1.4	0
208	Hospital Care of Pathological Vertebral Fracture (PVF) in Multiple Myeloma (MM) Patients: Burden of Illness and Patterns of Care. Blood, 2008, 112, 2409-2409.	1.4	0
209	Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL) Blood, 2008, 112, 2170-2170.	1.4	0
210	Allogeneic Stem Cell Transplantation for Patients with Chemo-Refractory or Progressive Aggressive Non-Hodgkin's Lymphomas Blood, 2008, 112, 3265-3265.	1.4	0
211	Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma Blood, 2009, 114, 4641-4641.	1.4	0
212	p53-Inducible Micrornas 192 and 215 Regulate p53 Expression and IGF1 Axis in Multiple Myeloma Blood, 2009, 114, 1973-1973.	1.4	0
213	Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study. Blood, 2010, 116, 1343-1343.	1.4	0
214	Tablet-Based Assessment of Fatigue, Depression, and Pain In Myeloma Patients: Cohort Study of Inflammatory Cytokines and QOL Measures In the Newly Diagnosed, Patients on Lenalidomide, and Survivors Blood, 2010, 116, 3807-3807.	1.4	0
215	The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development. Blood, 2011, 118, 1024-1024.	1.4	0
216	Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma. Blood, 2012, 120, 4460-4460.	1.4	0

#	Article	IF	CITATIONS
217	miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients Blood, 2012, 120, 2921-2921.	1.4	0
218	Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease. Blood, 2012, 120, 1949-1949.	1.4	0
219	Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma Blood, 2012, 120, 3114-3114.	1.4	Ο
220	FLT3L and AMD3100 Combination Increases Hematopoietic Stem Cell Mobilization and Leads To Improved Transplantation Outcome. Blood, 2013, 122, 901-901.	1.4	0
221	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). Blood, 2013, 122, 3185-3185.	1.4	0
222	Understanding The Differential Response Of Multiple Myeloma To Reovirus Treatment. Blood, 2013, 122, 3232-3232.	1.4	0
223	Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 2494-2494.	1.4	0
224	Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT). Blood, 2014, 124, 3929-3929.	1.4	0
225	Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers. Blood, 2015, 126, 1814-1814.	1.4	0
226	The Majority of Myeloma Patients Are Hypogonadal but This Is Not Associated with High Risk Cytogenetics. Blood, 2015, 126, 5329-5329.	1.4	0
227	Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development. Blood, 2015, 126, 1791-1791.	1.4	0
228	Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT). Blood, 2015, 126, 4328-4328.	1.4	0
229	Relative Clone Size By FISH of Both Del(13q) and Del(17p) Independently Impact Overall Survival. Blood, 2016, 128, 4444-4444.	1.4	0
230	Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation. Blood, 2016, 128, 3409-3409.	1.4	0
231	Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 1241-1241.	1.4	0
232	Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation. Blood, 2016, 128, 3410-3410.	1.4	0
233	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. Blood, 2018, 132, 3302-3302.	1.4	0
234	The Role of Proteasome Activator PA28α in Multiple Myeloma. Blood, 2019, 134, 5499-5499.	1.4	0

#	Article	IF	CITATIONS
235	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) Tj ETQq1 1	0.7 /84 /314	rgðT /Overlo
236	Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients. Blood, 2021, 138, 1616-1616.	1.4	0
237	BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. Blood, 2021, 138, 1624-1624.	1.4	0
238	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) Tj ETQq0 C	0 rggBr /Ov	verlock 10 Tf
239	Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma. Blood, 2020, 136, 31-32.	1.4	0
240	Role of clonoSEQ®, a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma. Blood, 2020, 136, 50-51.	1.4	0
241	Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT) , 2019, 2, 12-18.		0